Monocyte chemoattractant protein-1 predicts outcome and vasospasm following aneurysmal subarachnoid hemorrhage

Grace H. Kim, Christopher P. Kellner, David K. Hahn, Brianna M. Desantis, Muhith Musabbir, Robert M. Starke, Michal Rynkowski, Ricardo J Komotar, Marc L. Otten, Robert Sciacca, J. Michael Schmidt, Stephan A. Mayer, E. Sander Connolly

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Object. Despite efforts to elucidate both the molecular mechanism and the clinical predictors of vasospasm after aneurysmal subarachnoid hemorrhage (ASAH), its pathogenesis remains unclear. Monocyte chemoattractant protein-1 (MCP-1) is a chemokine that has been firmly implicated in the pathophysiology of vasospasm and in neural tissue injury following focal ischemia in both animal models and human studies. The authors hypothesized that MCP-1 would be found in increased concentrations in the blood and cerebrospinal fluid (CSF) of patients with ASAH and would correlate with both outcome and the occurrence of vasospasm. Methods. Seventy-seven patients who presented with ASAH were prospectively enrolled in this study between July 2001 and May 2002. Using an enzyme-linked immunosorbent assay, MCP-1 levels were measured in serum daily and in CSF when available. The mean serum and CSF MCP-1 concentrations were calculated for each patient throughout the entire hospital stay. Neurological outcome was evaluated at discharge or 14 days posthemorrhage using the modified Rankin Scale. Vasospasm was evaluated on angiography. Results. The serum MCP-1 concentrations correlated with negative outcome such that a 10% increase in concentration predicted a 25% increase in the probability of a poor outcome, whereas the serum MCP-1 levels did not correlate with vasospasm. Concentrations of MCP-1 in the CSF, however, proved to be significantly higher in patients with angiographically demonstrated vasospasm. Conclusions. These findings suggest a role for MCP-1 in neurological injury and imply that it may act as a biomarker of poor outcome in the serum and of vasospasm in the CSF.

Original languageEnglish
Pages (from-to)38-43
Number of pages6
JournalJournal of Neurosurgery
Volume109
Issue number1
DOIs
StatePublished - Jul 1 2008
Externally publishedYes

Fingerprint

Chemokine CCL2
Subarachnoid Hemorrhage
Cerebrospinal Fluid
Blood Proteins
Serum
Cerebrospinal Fluid Proteins
Wounds and Injuries
Chemokines
Length of Stay
Angiography
Ischemia
Animal Models
Biomarkers
Enzyme-Linked Immunosorbent Assay

Keywords

  • Monocyte chemoattractant protein-1
  • Subarachnoid hemorrhage
  • Vasospasm

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Neuroscience(all)

Cite this

Kim, G. H., Kellner, C. P., Hahn, D. K., Desantis, B. M., Musabbir, M., Starke, R. M., ... Connolly, E. S. (2008). Monocyte chemoattractant protein-1 predicts outcome and vasospasm following aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery, 109(1), 38-43. https://doi.org/10.3171/JNS/2008/109/7/0038

Monocyte chemoattractant protein-1 predicts outcome and vasospasm following aneurysmal subarachnoid hemorrhage. / Kim, Grace H.; Kellner, Christopher P.; Hahn, David K.; Desantis, Brianna M.; Musabbir, Muhith; Starke, Robert M.; Rynkowski, Michal; Komotar, Ricardo J; Otten, Marc L.; Sciacca, Robert; Schmidt, J. Michael; Mayer, Stephan A.; Connolly, E. Sander.

In: Journal of Neurosurgery, Vol. 109, No. 1, 01.07.2008, p. 38-43.

Research output: Contribution to journalArticle

Kim, GH, Kellner, CP, Hahn, DK, Desantis, BM, Musabbir, M, Starke, RM, Rynkowski, M, Komotar, RJ, Otten, ML, Sciacca, R, Schmidt, JM, Mayer, SA & Connolly, ES 2008, 'Monocyte chemoattractant protein-1 predicts outcome and vasospasm following aneurysmal subarachnoid hemorrhage', Journal of Neurosurgery, vol. 109, no. 1, pp. 38-43. https://doi.org/10.3171/JNS/2008/109/7/0038
Kim, Grace H. ; Kellner, Christopher P. ; Hahn, David K. ; Desantis, Brianna M. ; Musabbir, Muhith ; Starke, Robert M. ; Rynkowski, Michal ; Komotar, Ricardo J ; Otten, Marc L. ; Sciacca, Robert ; Schmidt, J. Michael ; Mayer, Stephan A. ; Connolly, E. Sander. / Monocyte chemoattractant protein-1 predicts outcome and vasospasm following aneurysmal subarachnoid hemorrhage. In: Journal of Neurosurgery. 2008 ; Vol. 109, No. 1. pp. 38-43.
@article{f223f0193ff44f099176564f141c87ac,
title = "Monocyte chemoattractant protein-1 predicts outcome and vasospasm following aneurysmal subarachnoid hemorrhage",
abstract = "Object. Despite efforts to elucidate both the molecular mechanism and the clinical predictors of vasospasm after aneurysmal subarachnoid hemorrhage (ASAH), its pathogenesis remains unclear. Monocyte chemoattractant protein-1 (MCP-1) is a chemokine that has been firmly implicated in the pathophysiology of vasospasm and in neural tissue injury following focal ischemia in both animal models and human studies. The authors hypothesized that MCP-1 would be found in increased concentrations in the blood and cerebrospinal fluid (CSF) of patients with ASAH and would correlate with both outcome and the occurrence of vasospasm. Methods. Seventy-seven patients who presented with ASAH were prospectively enrolled in this study between July 2001 and May 2002. Using an enzyme-linked immunosorbent assay, MCP-1 levels were measured in serum daily and in CSF when available. The mean serum and CSF MCP-1 concentrations were calculated for each patient throughout the entire hospital stay. Neurological outcome was evaluated at discharge or 14 days posthemorrhage using the modified Rankin Scale. Vasospasm was evaluated on angiography. Results. The serum MCP-1 concentrations correlated with negative outcome such that a 10{\%} increase in concentration predicted a 25{\%} increase in the probability of a poor outcome, whereas the serum MCP-1 levels did not correlate with vasospasm. Concentrations of MCP-1 in the CSF, however, proved to be significantly higher in patients with angiographically demonstrated vasospasm. Conclusions. These findings suggest a role for MCP-1 in neurological injury and imply that it may act as a biomarker of poor outcome in the serum and of vasospasm in the CSF.",
keywords = "Monocyte chemoattractant protein-1, Subarachnoid hemorrhage, Vasospasm",
author = "Kim, {Grace H.} and Kellner, {Christopher P.} and Hahn, {David K.} and Desantis, {Brianna M.} and Muhith Musabbir and Starke, {Robert M.} and Michal Rynkowski and Komotar, {Ricardo J} and Otten, {Marc L.} and Robert Sciacca and Schmidt, {J. Michael} and Mayer, {Stephan A.} and Connolly, {E. Sander}",
year = "2008",
month = "7",
day = "1",
doi = "10.3171/JNS/2008/109/7/0038",
language = "English",
volume = "109",
pages = "38--43",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

TY - JOUR

T1 - Monocyte chemoattractant protein-1 predicts outcome and vasospasm following aneurysmal subarachnoid hemorrhage

AU - Kim, Grace H.

AU - Kellner, Christopher P.

AU - Hahn, David K.

AU - Desantis, Brianna M.

AU - Musabbir, Muhith

AU - Starke, Robert M.

AU - Rynkowski, Michal

AU - Komotar, Ricardo J

AU - Otten, Marc L.

AU - Sciacca, Robert

AU - Schmidt, J. Michael

AU - Mayer, Stephan A.

AU - Connolly, E. Sander

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Object. Despite efforts to elucidate both the molecular mechanism and the clinical predictors of vasospasm after aneurysmal subarachnoid hemorrhage (ASAH), its pathogenesis remains unclear. Monocyte chemoattractant protein-1 (MCP-1) is a chemokine that has been firmly implicated in the pathophysiology of vasospasm and in neural tissue injury following focal ischemia in both animal models and human studies. The authors hypothesized that MCP-1 would be found in increased concentrations in the blood and cerebrospinal fluid (CSF) of patients with ASAH and would correlate with both outcome and the occurrence of vasospasm. Methods. Seventy-seven patients who presented with ASAH were prospectively enrolled in this study between July 2001 and May 2002. Using an enzyme-linked immunosorbent assay, MCP-1 levels were measured in serum daily and in CSF when available. The mean serum and CSF MCP-1 concentrations were calculated for each patient throughout the entire hospital stay. Neurological outcome was evaluated at discharge or 14 days posthemorrhage using the modified Rankin Scale. Vasospasm was evaluated on angiography. Results. The serum MCP-1 concentrations correlated with negative outcome such that a 10% increase in concentration predicted a 25% increase in the probability of a poor outcome, whereas the serum MCP-1 levels did not correlate with vasospasm. Concentrations of MCP-1 in the CSF, however, proved to be significantly higher in patients with angiographically demonstrated vasospasm. Conclusions. These findings suggest a role for MCP-1 in neurological injury and imply that it may act as a biomarker of poor outcome in the serum and of vasospasm in the CSF.

AB - Object. Despite efforts to elucidate both the molecular mechanism and the clinical predictors of vasospasm after aneurysmal subarachnoid hemorrhage (ASAH), its pathogenesis remains unclear. Monocyte chemoattractant protein-1 (MCP-1) is a chemokine that has been firmly implicated in the pathophysiology of vasospasm and in neural tissue injury following focal ischemia in both animal models and human studies. The authors hypothesized that MCP-1 would be found in increased concentrations in the blood and cerebrospinal fluid (CSF) of patients with ASAH and would correlate with both outcome and the occurrence of vasospasm. Methods. Seventy-seven patients who presented with ASAH were prospectively enrolled in this study between July 2001 and May 2002. Using an enzyme-linked immunosorbent assay, MCP-1 levels were measured in serum daily and in CSF when available. The mean serum and CSF MCP-1 concentrations were calculated for each patient throughout the entire hospital stay. Neurological outcome was evaluated at discharge or 14 days posthemorrhage using the modified Rankin Scale. Vasospasm was evaluated on angiography. Results. The serum MCP-1 concentrations correlated with negative outcome such that a 10% increase in concentration predicted a 25% increase in the probability of a poor outcome, whereas the serum MCP-1 levels did not correlate with vasospasm. Concentrations of MCP-1 in the CSF, however, proved to be significantly higher in patients with angiographically demonstrated vasospasm. Conclusions. These findings suggest a role for MCP-1 in neurological injury and imply that it may act as a biomarker of poor outcome in the serum and of vasospasm in the CSF.

KW - Monocyte chemoattractant protein-1

KW - Subarachnoid hemorrhage

KW - Vasospasm

UR - http://www.scopus.com/inward/record.url?scp=48049086124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049086124&partnerID=8YFLogxK

U2 - 10.3171/JNS/2008/109/7/0038

DO - 10.3171/JNS/2008/109/7/0038

M3 - Article

VL - 109

SP - 38

EP - 43

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 1

ER -